Tumor localization and systemic absorption of intravesical instillation of radio-iodinated iododeoxyuridine in patients with bladder cancer

Journal of Urology

Volumn 162, Issue 1, 1999, Pages 58-62

  Chiou, Rei K ^a   Dalrymple, Glenn V ^a   Baranowska Kortylewicz, Janina ^a   Holdeman, Karen P ^a   Schneiderman, Martin H ^a   Harrison, Katherine A ^a   Taylor, Rodney J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bladder; Idoxuridine; Neoplasm, bladder; Radionuclide imaging

Indexed keywords

IDOXURIDINE; RADIOISOTOPE;

AGED; ARTICLE; BLADDER CANCER; CLINICAL ARTICLE; CYSTECTOMY; DRUG ABSORPTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVESICAL DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; TUMOR LOCALIZATION; TUMOR SCINTISCANNING; UROGENITAL SCINTISCANNING;

EID: 0032845162     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005392-199907000-00015     Document Type: Article

References (24)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1998. CA, 48: 6, 1998.
2. Hudson, M. A. and Catalona, W. J.: Urothelial tumors of the bladder, upper tracts, and prostate. In: Adult and Pediatric Urology, 3rd ed. Edited by J. Y. Gillenwater, J. T. Grayhack, S. S. Howards and J. W. Duckett. St. Louis: Mosby Yearbook, pp. 1379-1464, 1996.
3. Geselowitz, D. A., McManaway, M. E., Hofer, K. G. and Neumann, R. D.: The cytotoxicity of decays of tritium and iodine-125 incorporated in DNA of mammalian cells. Implications for the low-LET dosimetry of incorporated nuclides. Rad. Res., 142: 321, 1995.
4. Neshasteh-Riz, A., Angerson, W. J., Reeves, J. R., Smith, G., Rampling, R. and Mairs, R. J.: Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Brit. J. Cancer, 75: 493, 1997.
5. Humm, J. L., Bagshawe, K. D., Sharma, S. K. and Boxer, G.: Tissue dose estimates following the selective uptake of 125IUdR and other radiolabelled thymidine precursors in resistant tumors. Brit. J. Rad., 64: 45, 1991.
6. Commerford, S. L., Bond, V. P., Cronkite, E. P. and Reincke, U.: Radiotoxicity of intranuclear 1251 atoms not bound to DNA. Int. J. Rad., 37: 547, 1980.
7. Keough, G. and Hofer, K. G.: Molecular consequences of the Auger effect: the fate of iododeoxyuridine following iodine-125 decay. Rad. Res., 67: 224, 1976.
8. Hofer, K. G.: Biophysical aspects of Auger processes: a review. Acta Oncol., 35: 789, 1996.
9. Harrison, K. A., Dalrymple, G. V., Baranowska-Kortylewicz, J., Holdeman, K. P., Schneiderman, M. H., Lieberman, R. P., Sharp, J. G., Cohen, S. M., Leichner, P. K., Augustine, S. C., Tempero, M. A., Taylor, R. J. and Chiou, R. K.: Radiolabeled iododeoxyuridine: safety evaluation. J. Nucl. Med., suppl., 37: 13S, 1996.
10. 131I labeled carrier-free 5-iodo-2′-deoxyuridine, J. Lab. Comp. Radiopharmacol., 14: 83, 1978.
11. Shipley, W. U., Prout, G. R., Jr. and Kaufman, D. S.: Bladder cancer: advances in laboratory innovations and clinical management, with emphasis on innovations allowing bladder-sparing approaches for patients with invasive tumors. Cancer, suppl., 65: 675, 1990.
12. 123I]iodo-2′-deoxyuridine in the radiotherapy of an early ascites tumor model. Int. J. Rad., 21: 1541, 1991.
13. Philip, P. A., Bagshawe, K. D., Searle, F., Green, A. J., Begent, R. H., Newlando, E. S., Rustin, G. J. and Adani, T.: In vivo uptake of 131 I-5-iodo-2-deoxyuridme by malignant tumours in man. Brit. J. Cancer, 63: 134, 1991.
14. Macapinlac, H., Scott, A., Daghighian, F., Yeh, S., Ginos, J., Tjuvajev, J., Zhang, J., Finn, R., Larson, S. and Blasberg, R.: Assessment of brain tumor proliferative activity using I-131-iododeoxyuridine (IUDR). J. Nucl. Med., 34: 37P, 1993.
15. 125]iodo-2′-deoxyuridine following intratumoral injection in patients with colorectal cancer. J. Nucl. Med., 34: 1175, 1993.
16. Schneiderman, M. H. and Schneiderman, G. S.: Radio-iododeoxyuridine in cancer therapy: an in vitro approach to developing in vivo strategies. J. Nucl. Med., suppl., 37: 6S, 1996.
17. 125I] iodo-2′-deoxyuridine in cancer. AAMP Monograph, Proceedings of the 2nd International Symposium on Biophysical Aspects of Auger Processes. Amherst, Massachusetts, 1991.
18. Holdeman, K., Chiou, R., Cohen, S., Harrison, K., Kostylewicz, J., Schneiderman, M. H., Sharp, J. G., Taylor, R. and Dalrymple, G. V.: Radioiodinated iododeoxyuridine (IUDR) for the identification and therapy of residual bladder cancer. Int. J. Rad. Biol., 68: 354, 1995.
19. 125I]Iodo-2′-deoxyuridine - pre-clinical evaluation in swine. Acta Oncol., 35: 925, 1996.
20. 125I-Iodo-2′-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J. Nucl. Med., suppl., 37: 25S, 1996.
21. Humm, J. L., Howell, R. W. and Rao, D. V.: Dosimetry of Auger-electron-emitting radionuclides: report No. 3 of AAPM Nuclear Medicine Task Group No. 6. Med. Phy., 21: 1901,1994.
22. Mariani, G., Collecchi, P., Baldassarri, S., Di Luca, L., Buralli, S., Fontanini, G., Baranowska-Kortylewicz, J., Adelstein, S. J. and Kassis, A. I.: Tumor uptake and mitotic activity pattern of 5-[125I] iodo-2′-deoxyuridine after intravesical infusion in patients with bladder cancer. J. Nucl. Med., suppl., 37: 16S,1996.
23. Kurth, K., Tunn, U., Ay, R., Schröder, F. H., Pavone-Macaluso, M., Debruyne, F., Ten Kate, F., De Pauw, M., Sylvester, R. and members of the European Organization for Research and Treatment of Cancer Genitourinary Group: Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J. Urol., 158: 378, 1997.
24. Klän, R., Loy, V. and Huland, H.: Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J. Urol., 146: 316, 1991.